argenx SE ARGX
981.79 USD +4.21 (+0.43%)
Nov 12, 2026, 3:42 PM EST
964.86 Day range 988.89
663.93 52-week range 1,058.90
- YTD
- +16.75%
- 1 year
- +10.33%
News
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX NEW YORK, Nov. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of argenx SE ("argenx" or the "Company") (NASDAQ: ARGX). Such investors are advised to contact…
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX NEW YORK, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of argenx SE (“argenx” or the “Company”) (NASDAQ: ARGX). Such investors are advised to contact…
benzinga.com If You Invested $100 In argenx Stock 5 Years Ago, You Would Have This Much Today argenx (NASDAQ:ARGX) has outperformed the market over the past 5 years by 15.47% on an annualized basis producing an average annual return of 25.51%. Currently, argenx has a market capitalization of…
fool.com 3 Reasons Argenx Could Be a Top Biotech Stock for the Next Decade Argenx's Vyvgart franchise addresses about 28,000 patients today, with the company targeting 60,000 by 2030. The biotech is solidly profitable, with Q3 revenue up 54% and $3.7 billion in cash to fund…
benzinga.com Reported Saturday, argenx Plans To Submit Supplemental BLA For Efgartigimod In IMNM By End Of 2026 After Phase 3 ALKIVIA Shows 14.8-Point Greater TIS Improvement Versus Placebo At Week 52 ALKIVIA met its primary and key secondary endpoints in the combined IMNM and DM populationFirst Phase 3 study to demonstrate statistically significant and clinically meaningful benefit in IMNM, an…
benzinga.com Argenx To Acquire Unnatural Products For Up To ~$1.15B Including $550M Upfront And Up To $595M In Milestones, Adding Peptide Discovery Engine Pairs Unnatural Products’ (UNP) peptide expertise with argenx's antibody engineering, expanding the ways to target novel biology Extends argenx’s immunology innovation to more patients, with the…
globenewswire.com Unnatural Products to be Acquired by argenx for up to $1.15 Billion to Advance Next-Generation Medicines Argenx to acquire UNP for $550 million upfront plus contingent value rights tied to development and regulatory milestones, for total potential value of up to approximately $1.15 billion
globenewswire.com argenx to Acquire Unnatural Products, Inc., Adding Peptide Discovery Engine to Broaden Immunology Capabilities Amsterdam, the Netherlands, November 9, 2026, 07:00 CET – argenx (Euronext & Nasdaq: ARGX), the immunology innovation company, today announced a definitive agreement to acquire Unnatural Products,…
globenewswire.com argenx Presents Phase 3 ALKIVIA Data at ACR Convergence 2026 Showing Rapid and Sustained Improvement with Efgartigimod in Autoimmune Myositis ALKIVIA met its primary and key secondary endpoints in the combined IMNM and DM population First Phase 3 study to demonstrate statistically significant and clinically meaningful benefit in IMNM, an…
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX NEW YORK, Nov. 5, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of argenx SE ("argenx" or the "Company") (NASDAQ: ARGX). Such investors are advised to contact…
benzinga.com Citigroup Maintains Buy on argenx, Lowers Price Target to $1232 Citigroup analyst Samantha Semenkow maintains argenx (NASDAQ:ARGX) with a Buy and lowers the price target from $1301 to $1232.
benzinga.com $1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today argenx (NASDAQ:ARGX) has outperformed the market over the past 5 years by 12.9% on an annualized basis producing an average annual return of 23.66%. Currently, argenx has a market capitalization of…
benzinga.com Morgan Stanley Maintains Overweight on argenx, Raises Price Target to $1190 Morgan Stanley analyst Sean Laaman maintains argenx (NASDAQ:ARGX) with a Overweight and raises the price target from $1140 to $1190.- benzinga.com Guggenheim Maintains Buy on argenx, Lowers Price Target to $1120 Guggenheim analyst Yatin Suneja maintains argenx (NASDAQ:ARGX) with a Buy and lowers the price target from $1185 to $1120.
- benzinga.com Wells Fargo Maintains Overweight on argenx, Lowers Price Target to $1336 Wells Fargo analyst Derek Archila maintains argenx (NASDAQ:ARGX) with a Overweight and lowers the price target from $1356 to $1336.
- benzinga.com Evercore ISI Group Maintains Outperform on argenx, Raises Price Target to $1090 Evercore ISI Group analyst Gavin Clark-Gartner maintains argenx (NASDAQ:ARGX) with a Outperform and raises the price target from $1078 to $1090.
benzinga.com Procter & Gamble To Rally Over 12%? Here Are 10 Top Analyst Forecasts For Friday Analysts cut EAT, TTMI and MRTN targets, while raising SPOT, RBLX, S, PG and ARGX; ratings were largely maintained.- benzinga.com Baird Maintains Neutral on argenx, Raises Price Target to $861 Baird analyst Colleen Kusy maintains argenx (NASDAQ:ARGX) with a Neutral and raises the price target from $823 to $861.
benzinga.com argenx Q3 2026 Earnings Call Transcript argenx (NASDAQ:ARGX) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
benzinga.com argenx Q3 EPS $7.80 Misses $7.83 Estimate, Sales $1.751B Beat $1.664B Estimate argenx (NASDAQ:ARGX) reported quarterly earnings of $7.80 per share which missed the analyst consensus estimate of $7.83 by 0.38 percent. This is a 50.58 percent increase over earnings of $5.18 per…
benzinga.com Procter & Gamble, Western Digital On Deck Thursday As Growth, AI Demand Face Test Procter & Gamble headlines Thursday’s reports, with investors weighing resilient consumer demand against cost pressures and softer earnings growth. Union Pacific, Lockheed Martin, Valero Energy and…
benzinga.com RBC Capital Maintains Outperform on argenx, Lowers Price Target to $1025 RBC Capital analyst Luca Issi maintains argenx (NASDAQ:ARGX) with a Outperform and lowers the price target from $1100 to $1025.- benzinga.com argenx SE To Present New Data From Phase 3 Study Evaluating VYVGART Hytrulo In Patients With Autoimmune Myositis, Focused On IMNM And DM, At ACR Convergence 2026 Results from the global Phase 3 ALKIVIA study, the first registrational study investigating an FcRn blocker in autoimmune myositis, show efgartigimod provides clinically meaningful improvements in…
- benzinga.com Wells Fargo Maintains Overweight on argenx, Raises Price Target to $1356 Wells Fargo analyst Derek Archila maintains argenx (NASDAQ:ARGX) with a Overweight and raises the price target from $1355 to $1356.
- benzinga.com Oppenheimer Maintains Outperform on argenx, Lowers Price Target to $1038 Oppenheimer analyst Leland Gershell maintains argenx (NASDAQ:ARGX) with a Outperform and lowers the price target from $1100 to $1038.
- benzinga.com Evercore ISI Group Maintains Outperform on argenx, Lowers Price Target to $1078 Evercore ISI Group analyst Gavin Clark-Gartner maintains argenx (NASDAQ:ARGX) with a Outperform and lowers the price target from $1175 to $1078.
- benzinga.com Baird Maintains Neutral on argenx, Lowers Price Target to $823 Baird analyst Colleen Kusy maintains argenx (NASDAQ:ARGX) with a Neutral and lowers the price target from $932 to $823.
benzinga.com $100 Invested In argenx 5 Years Ago Would Be Worth This Much Today argenx (NASDAQ:ARGX) has outperformed the market over the past 5 years by 10.42% on an annualized basis producing an average annual return of 22.71%. Currently, argenx has a market capitalization of…
benzinga.com Crude Oil Gains 5%; PepsiCo Posts Upbeat Q3 Earnings U.S. stocks fell Thursday as Nasdaq slid 150+ points; energy rallied, healthcare dropped. PepsiCo beat estimates but cut FY26 outlook; oil jumped 5%.
benzinga.com Argenx Halts Phase 3 Study in Rare Disease Following Futility Analysis Argenx announced Phase 2 success for FB102 in celiac disease while halting its Phase 3 UNITY study in Sjögren's disease for futility.
benzinga.com Argenx, Caribou Biosciences And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session U.S. stock futures fell, with Dow futures down 450 points. Argenx sank 8.7% after a Sjögren’s trial was halted for futility; others also slid.
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Profound Medical (NASDAQ:PROF) shares moved upwards by 21.5% to $6.9 during Thursday's pre-market session. The company's market cap stands at $207.5 million. Haemonetics (NYSE:HAE) stock…
benzinga.com Why Applied Digital Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket Applied Digital shares rise after Q1 revenue and loss beat estimates; Xiao-I and iPower lead gainers, while China SXT and Medicus Pharma fall.
benzinga.com Argenx's FB102 Meets Primary Endpoint In Phase 2 Celiac Disease Study Versus Placebo With No New Safety Signals; Company Will Advance First-In-Class CD122 Inhibitor Into Phase 3 Development Study met primary endpoint of change from baseline in the ratio of Vh:Cd (p=0.0176)First Phase 2 evidence that blocking CD122 can prevent gluten-induced intestinal damage in people living with celiac…- benzinga.com Halozyme Therapeutic Expands Collaboration, License Deal With Argenx Over Development, Commercialization Of ENHANCE With Two Additional Targets Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced that it has expanded its global collaboration and license agreement with argenx to develop and commercialize
benzinga.com Here's How Much $100 Invested In argenx 5 Years Ago Would Be Worth Today argenx (NASDAQ:ARGX) has outperformed the market over the past 5 years by 14.22% on an annualized basis producing an average annual return of 26.19%. Currently, argenx has a market capitalization of…- benzinga.com Wedbush Reiterates Outperform on argenx, Maintains $1150 Price Target Wedbush analyst David Nierengarten reiterates argenx (NASDAQ:ARGX) with a Outperform and maintains $1150 price target.
- benzinga.com Here's How Much $100 Invested In argenx 5 Years Ago Would Be Worth Today argenx (NASDAQ:ARGX) has outperformed the market over the past 5 years by 13.58% on an annualized basis producing an average annual return of 24.86%. Currently, argenx has a market capitalization of…
benzinga.com Wedbush Reiterates Outperform on argenx, Maintains $1150 Price Target Wedbush analyst David Nierengarten reiterates argenx (NASDAQ:ARGX) with a Outperform and maintains $1150 price target.- benzinga.com Morgan Stanley Maintains Overweight on argenx, Raises Price Target to $1250 Morgan Stanley analyst Sean Laaman maintains argenx (NASDAQ:ARGX) with a Overweight and raises the price target from $1230 to $1250.
- benzinga.com UBS Upgrades argenx to Buy, Raises Price Target to $1400 UBS analyst Xian Deng upgrades argenx (NASDAQ:ARGX) from Neutral to Buy and raises the price target from $960 to $1400.
- benzinga.com Wells Fargo Maintains Overweight on argenx, Raises Price Target to $1415 Wells Fargo analyst Derek Archila maintains argenx (NASDAQ:ARGX) with a Overweight and raises the price target from $1350 to $1415.
- benzinga.com Truist Securities Maintains Buy on argenx, Raises Price Target to $1095 Truist Securities analyst Danielle Brill maintains argenx (NASDAQ:ARGX) with a Buy and raises the price target from $1030 to $1095.
- benzinga.com RBC Capital Maintains Outperform on argenx, Raises Price Target to $1100 RBC Capital analyst Luca Issi maintains argenx (NASDAQ:ARGX) with a Outperform and raises the price target from $1025 to $1100.
benzinga.com Snowflake To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. HC…
benzinga.com These Analysts Boost Their Forecasts On Argenx Argenx SE (NASDAQ:ARGX) reports positive Phase 3 results for VYVGART Hytrulo in autoimmune myositis. Analysts raise price targets on ARGX stock.- benzinga.com Citizens Maintains Market Outperform on argenx, Raises Price Target to $1200 Citizens analyst Jason N. Butler maintains argenx (NASDAQ:ARGX) with a Market Outperform and raises the price target from $932 to $1200.
- benzinga.com Wedbush Maintains Outperform on argenx, Raises Price Target to $1150 Wedbush analyst David Nierengarten maintains argenx (NASDAQ:ARGX) with a Outperform and raises the price target from $1050 to $1150.
- benzinga.com HC Wainwright & Co. Maintains Buy on argenx, Raises Price Target to $1202 HC Wainwright & Co. analyst Douglas Tsao maintains argenx (NASDAQ:ARGX) with a Buy and raises the price target from $940 to $1202.
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers INVO Fertility (NASDAQ:IVF) shares moved upwards by 108.9% to $2.03 during Monday's regular session. The market value of their outstanding shares is at $1.7 million. As per the press release,…